Company Overview

Lantheus Holdings, Inc. is a U.S.-based healthcare company focused on the development, manufacturing, and commercialization of diagnostic medical imaging agents, primarily within the nuclear medicine and molecular imaging industries. The company’s core business centers on radiopharmaceuticals and contrast agents used to support the diagnosis and characterization of cardiovascular and oncologic diseases. Its revenue is primarily driven by proprietary imaging products used in hospital, outpatient, and specialty imaging center settings.

Lantheus was founded in 1956 and has evolved from a traditional nuclear medicine supplier into a targeted molecular diagnostics company with a strong emphasis on oncology imaging. A significant inflection point in its evolution occurred with the expansion into prostate cancer diagnostics, particularly through PSMA-targeted PET imaging agents. The company’s strategic positioning is supported by established manufacturing infrastructure, regulatory expertise, and long-standing relationships with imaging providers.

Business Operations

Lantheus operates through integrated diagnostic imaging businesses focused on radiopharmaceuticals and ultrasound contrast agents. Key revenue-generating products include DEFINITY, an ultrasound enhancing agent for cardiac imaging, and PYLARIFY, a PSMA-targeted PET imaging agent for prostate cancer. Legacy nuclear cardiology products, including Cardiolite, continue to contribute revenue, though at a reduced level compared to historical performance.

Operations are primarily based in the United States, with select international distribution through partnerships and licensing arrangements. The company controls specialized manufacturing and radiochemistry capabilities, including cyclotron-based and generator-based production. A notable subsidiary is Progenics Pharmaceuticals, which was acquired to strengthen Lantheus’s oncology imaging portfolio and intellectual property base.

Strategic Position & Investments

Lantheus’s strategy emphasizes growth in precision diagnostics, particularly in oncology-focused molecular imaging. The commercial success of PYLARIFY has positioned the company as a leader in PSMA PET imaging for prostate cancer, and management has stated a continued focus on lifecycle management and label expansion within this franchise. The company also invests in next-generation radiopharmaceutical candidates designed to target high-unmet-need disease states.

Strategic investments include internal research and development as well as external collaborations and acquisitions aimed at expanding the diagnostic pipeline. Progenics Pharmaceuticals remains a key subsidiary supporting innovation in targeted imaging. Lantheus has also indicated interest in emerging radiotheranostic technologies, although the pace and scale of expansion beyond diagnostics varies by program and is subject to regulatory and clinical outcomes.

Geographic Footprint

Lantheus is headquartered in North America (United States) and generates the majority of its revenue domestically. Its products are widely used across U.S. hospitals, academic medical centers, and outpatient imaging facilities. Manufacturing and distribution infrastructure is primarily U.S.-based to support time-sensitive radiopharmaceutical logistics.

Internationally, Lantheus maintains a presence in parts of Europe, Asia-Pacific, and Latin America through distributors, licensees, and strategic partners. While international revenue represents a smaller portion of total sales, these markets provide incremental growth opportunities and broaden the global clinical adoption of the company’s diagnostic agents.

Leadership & Governance

Lantheus is led by an executive team with experience in pharmaceuticals, diagnostics, and regulated healthcare markets. The leadership emphasizes disciplined capital allocation, product innovation, and operational execution within highly regulated environments.

• Mary Anne Heino – President and Chief Executive Officer
• Paul Blanchfield – Chief Financial Officer
• Nicole Schmider – Chief Operating Officer
• Bob Marshall – Chief Technology Officer

The company operates under a shareholder-focused governance model, with strategic priorities centered on sustainable growth, compliance with regulatory standards, and expansion of clinically differentiated diagnostic solutions.